CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 11 enrolled
Drug / intervention
Losartan Potassium +1 moredrug
Likely dose
Losartan Potassium 50mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04632589
NCT04632589Early Ph 1Completed

Angiotensin II Receptor Inhibition to Improve Microvascular Function in Women Who Have Had Preeclampsia

Anna Stanhewicz, PhD·interventional·Posted Nov 17, 2020·Updated Jul 10, 2025

In Brief

A Early Phase 1 clinical trial evaluating Losartan Potassium and Placebo for Preeclampsia Postpartum. Completed, enrolled 11 participants across 1 site.

Detailed Summary

Women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs is unclear but may be related to blood vessel damage and increased inflammation that occurs during the preeclamptic pregnancy and persists postpartum. The purpose of this investigation is to determine the mechanisms contributing to this lasting blood vessel damage and to test whether taking a medication that blocks angiotensin II receptors (losartan) decrease these negative effects in women who have had preeclampsia. Identification of these mechanisms and treatment strategies may lead to better clinical management,of cardiovascular disease risk in these women. In this study we use the blood vessels in the skin as a representative vascular bed. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) we examine the blood vessels in a nickle-sized area of the skin in women who have had preeclampsia. We make these measurements after the subjects take a placebo and after they take losartan (an angiotensin II receptor blocker) to test whether this treatment improves vascular function in these women. As a compliment to these measurements, we also draw blood from the subjects and isolate the inflammatory cells to test how sensitive their inflammatory responses are following the placebo and the losartan treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Early Ph 1CompletedFinished
202120222023202420252026
First PostedNov 17, 2020
Enrollment StartNov 22, 2020
Primary CompletionJun 30, 2024
Study CompletionMar 13, 2025
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 5.6 years ago

Interventions

Losartan Potassiumdrug

subjects ingest 50mg losartan potassium tablet daily for 6 weeks

Placebodrug

subjects ingest placebo tablet daily for 6 weeks